GoodRx Sees Unusually Large Options Volume (NASDAQ:GDRX)

Key Points

• GoodRx Holdings, Inc. experienced a significant surge in options trading, with traders purchasing 11,377 call options, marking an increase of approximately 1,680% compared to its average volume.
• Major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock at an average price of $4.80, totaling over $51,000.
• The stock's performance saw it trading at $5.12 on Monday, with a market cap of $1.78 billion and institutional investors holding 63.77% of the company's shares.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) saw unusually large options trading activity on Monday. Stock investors bought 11,377 call options on the company. Thisrepresentsanincreaseofapproximately1,680% compared to the typical daily volume of 639 call options.

Analysts Set New Price Targets

GDRX has been the topic of a number of analyst reports. Raymond James Financial cut shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $6.00 target price on shares of GoodRx in a research note on Monday, August 11th. UBS Group cut their target price on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Wells Fargo & Company cut their target price on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Finally, The Goldman Sachs Group cut their target price on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Five investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $5.80.

Insider Buying and Selling

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total value of $51,249.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.53% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GDRX. Citizens Financial Group Inc. RI purchased a new position in shares of GoodRx during the first quarter valued at approximately $44,000. Jump Financial LLC purchased a new position in shares of GoodRx during the first quarter valued at approximately $49,000. Cetera Investment Advisers purchased a new position in shares of GoodRx during the second quarter valued at approximately $50,000. Walled Lake Planning & Wealth Management LLC purchased a new position in shares of GoodRx during the second quarter valued at approximately $55,000. Finally, Deerfield Management Company L.P. Series C purchased a new position in shares of GoodRx during the fourth quarter valued at approximately $56,000. Institutional investors own 63.77% of the company's stock.

GoodRx Stock Up 1.6%

NASDAQ:GDRX traded up $0.07 during mid-day trading on Friday, hitting $4.56. 4,460,833 shares of the company's stock were exchanged, compared to its average volume of 5,483,476. GoodRx has a one year low of $3.31 and a one year high of $8.80. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21. The business has a fifty day moving average price of $4.58 and a 200 day moving average price of $4.50. The company has a market cap of $1.58 billion, a PE ratio of 45.60, a P/E/G ratio of 1.99 and a beta of 1.24.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). The business had revenue of $203.07 million for the quarter, compared to the consensus estimate of $205.72 million. GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The company's revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.08 EPS. Equities analysts predict that GoodRx will post 0.13 EPS for the current year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.